British Journal of Medical & Surgical Urology
Volume 1, Issue 3 , Pages 126-130 , November 2008

The use of the NMP22 BladderChek test for bladder cancer to optimise investigations in a one-stop haematuria clinic

Received 10 June 2008 ,Revised 3 July 2008 ,Accepted 8 July 2008.

References 

  1. Mariani AJ, Mariani AC, Macchioni C, Stams UK, Hariharan A, Moriera A. The significance of adult haematuria: 1000 haematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol. 1989;141:350
  2. Identification, management and referral of adults with chronic kidney disease: concise guidelines. http://www.renal.org/CKDguide/full/Conciseguid141205.pdf.
  3. Rodgers MA, Hempel S, Aho T, Kelly JD, Kleijnen J, Westwood M. Diagnostic tests used in the investigation of adult haematuria: a systematic review. BJU Int. 2006;98(6):1154–1160
  4. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. A prospective analysis of 1930 patients with haematuria to evaluate current diagnostic practice. J Urol. 2000;163:524–527
  5. Goessl C, Knipsel HH, Miller K, Klan R. Is routine excretory urography necessary at first diagnosis of bladder cancer?. J Urol. 1997;157:480–481
  6. Datta SN, Allen GM, Evans R, Vaughton KC, Lucas MG. Urinary tract ultrasonography in the evaluation of haematuria—a report of over 1000 cases. Ann R Coll Surg Engl. 2002;84:203–205
  7. Viswanath S, Zlehof B, Ho E, Sethia K, Mills R. Is routine urine cytology useful in the haematuria clinic. Ann R Coll Surg Engl. 2008;90:153–155
  8. Rooke G, Gupta S, Potter J, Miller M, Bell R, Kunkler R. The role of urine cytology in the initial assessment of patients with haematuria. BJU Int. 2007;99(4):22
  9. Barrass B, Astall E, Sharma S, Blackford H. Urine cytology in the investigation of haematuria—is it really worth it?. BJU Int. 2007;99(4):22
  10. Murphy WM, Soloway MS, Jukkola AF, Crabtree WN, Ford KS. Urine cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer. 1984;53:1555–1565
  11. Farrow GM, Utz DC, Rife CC, Greene LF. Clinical observations on sixty-nine cases of in-situ carcinoma of the urinary bladder. Cancer Res. 1977;37:2794–2798
  12. Malik S, Murphy WM. Monitoring patients for bladder neoplasms: what can be expected of urine cytology consultations in daily practice?. Urology. 1999;54:62–66
  13. Raitanen MP, Aine R, Rintala E, Kallio J, Rajala P, Juusela H, et al. Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol. 2002;41(3):284–289
  14. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295(3):299–305
  15. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293(7):810–816
  16. Talwar R, Sinha T, Karan S, Doddamani D, Sandhu A, Sethi GS, et al. Voided urinary cytology in bladder cancer: is it time to review the indications. Urology. 2007;70(2):267–271
  17. Soloway M, Briggman J, Carpinito , Chodak GW, Church PA, Lamm DL, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. J Urol. 1996;156:363–367
  18. Poulakis V, Witzch U, DeVries R, Altmannsberger HM, Manyak MJ, Becht E. A comparison of urinary matrix protein-22 and bladder tumour antigen test with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false positive results. BJUI. 2001;88:692–701

PII: S1875-9742(08)00067-0

doi: 10.1016/j.bjmsu.2008.07.006

British Journal of Medical & Surgical Urology
Volume 1, Issue 3 , Pages 126-130 , November 2008

Article Tools